克罗恩病患者启动生物制剂后停用美沙拉嗪不增加不良结局风险
该研究基于美国Truven MarketScan和丹麦健康登记两个国家队列,纳入已用口服美沙拉嗪至少90天后启动抗TNF治疗的克罗恩病患者,比较停用与继续美沙拉嗪的临床不良事件风险。结果显示两个队列中停用美沙拉嗪均未与不良临床事件风险增加相关,作者建议前瞻性研究验证。
要点
- 敏感性分析(联用免疫调节剂及美沙拉嗪疗程)结果相似。
核心结论
- 在两个国家数据库的回顾性分析中,克罗恩病患者启动抗TNF治疗时停用美沙拉嗪未增加不良临床事件风险。
- 作者建议这些结果应在前瞻性研究中验证。
研究设计与样本
- 回顾性分析美国Truven MarketScan健康索赔数据库和丹麦健康登记两个国家队列。
- 最终分析纳入3178例克罗恩病患者(美国2960例,丹麦218例),均为口服美沙拉嗪至少90天后启动抗TNF治疗。
- 停用美沙拉嗪定义为启动抗TNF后90天内停用,采用多变量Cox回归模型控制人口学、临床因素和医疗利用情况。
主要发现
- 主要结局为任何不良临床事件,定义为新用糖皮质激素或克罗恩病相关住院或手术的复合终点。
- 联用免疫调节剂及启动抗TNF前美沙拉嗪疗程的敏感性分析结果相似。
关键数值与推荐
- 纳入标准:克罗恩病患者启动抗TNF治疗前已接受口服美沙拉嗪至少90天。
- 停用美沙拉嗪定义:启动抗TNF后90天内停用。
- 主要结局:新用糖皮质激素或克罗恩病相关住院或手术的复合终点。
临床怎么用
- 对于已用美沙拉嗪的克罗恩病患者,启动抗TNF治疗时停用美沙拉嗪未显示增加不良临床事件风险。
- 该结果来自回顾性数据库分析,作者建议在前瞻性研究中验证。
局限性
- 原文明确为回顾性分析(retrospective analysis)。
- 原文作者建议结果应在前瞻性研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Little is known about the effects of discontinuing mesalamine therapy for patients with Crohn's disease (CD) who initiate therapy with an anti-tumor necrosis factor (anti-TNF) agent. We analyzed data from 2 national population cohorts to compare outcomes of patients with CD already on mesalamine therapy who started treatment with an anti-TNF agent and then either stopped or continued mesalamine. METHODS: The primary outcome was any adverse clinical event, defined as a composite of new corticosteroid use or CD-related hospitalization or surgery. We collected data from the Truven MarketScan (IBM, Armonk, NY) health claims database in the United States and the Danish health registers. Our analysis included patients with CD who started anti-TNF therapy after at least 90 days of oral mesalamine therapy. Patients were classified as stopping mesalamine if therapy was discontinued within 90 days of starting anti-TNF. We performed multivariable Cox regression models controlling for demographics, clinical factors, and health care utilization. Adjusted hazard ratios with 95% CIs were calculated, comparing stopping mesalamine with continuing mesalamine. RESULTS: A total of 3178 patients with CD were included in our final analysis (2960 in the United States and 218 in Denmark). Stopping mesalamine after initiating anti-TNF therapy was not associated with an increased risk of adverse clinical events in the US cohort (adjusted hazard ratio, 0.89; 95% CI, 0.77-1.03; P = .13) or in the Danish cohort (adjusted hazard ratio, 1.13; 95% CI, 0.68-1.87; P = .63). Similar results were obtained from sensitivity analyses of concomitant immunomodulator use and duration of mesalamine treatment before initiation of anti-TNF therapy. CONCLUSIONS: In a retrospective analysis of 2 national databases, we found that stopping mesalamine therapy for patients with CD who were starting anti-TNF therapy did not increase their risk of adverse clinical events. These results should be validated in a prospective study.
引用
- Ungaro RC, Limketkai BN, Jensen CB, et al. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. Clin Gastroenterol Hepatol. 2019. PMID: 31419574. doi:10.1016/j.cgh.2019.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。